Crossref
Brentuksimab Vedotin Treatment in Relaps Refractory Hodgkin Lymphoma: A Single Center Experience
LLM Dergi · 2021
DOI: 10.5578/llm.20219802 ↗Kurz gefasst
Fachartikel in der Zeitschrift LLM Dergi, 2021. Verfasst von Derya Koyun und 12 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Koyun, D., Seval, G. C., Sökmen, M., Akkuş, E., Atilla, E., Bozdağ, S. C., Topçuoğlu, P., Arslan, Ö., Demirer, T., Gürman, G., İlhan, O., Beksaç, M., & Toprak, S. K. (2021). Brentuksimab Vedotin Treatment in Relaps Refractory Hodgkin Lymphoma: A Single Center Experience. LLM Dergi. https://doi.org/10.5578/llm.20219802
Vancouver
Koyun D, Seval GC, Sökmen M, Akkuş E, Atilla E, Bozdağ SC, et al. Brentuksimab Vedotin Treatment in Relaps Refractory Hodgkin Lymphoma: A Single Center Experience. LLM Dergi. 2021. doi:10.5578/llm.20219802
BibTeX
@article{Koyun2021,
author = {Koyun, Derya and Seval, Güldane Cengiz and Sökmen, Metin and Akkuş, Erman and Atilla, Erden and Bozdağ, Sinem Civriz and Topçuoğlu, Pervin and Arslan, Önder and Demirer, Taner and Gürman, Günhan and İlhan, Osman and Beksaç, Meral and Toprak, Selami Koçak},
title = {Brentuksimab Vedotin Treatment in Relaps Refractory Hodgkin Lymphoma: A Single Center Experience},
journal = {LLM Dergi},
year = {2021},
doi = {10.5578/llm.20219802}
}
EUVIMED